Quality of life in adults with brain tumors: current knowledge and future directions.

Department of Neurological Surgery, University of California, San Francisco, CA 94143-0350, USA.
Neuro-Oncology (Impact Factor: 5.29). 12/2008; 11(3):330-9. DOI: 10.1215/15228517-2008-093
Source: PubMed

ABSTRACT Quality of life is an important area of clinical neurooncology that is increasingly relevant as survivorship increases and as patients experience potential morbidities associated with new therapies. This review of quality-of-life studies in the brain tumor population aims to summarize what is currently known about quality of life in patients with both low-grade and high-grade tumors and suggest how we may use this knowledge to direct future research. To date, reports on quality of life have been primarily qualitative and focused on specific symptoms such as fatigue, sleep disorders, and cognitive dysfunction, as well as some symptom clusters. However, the increasing interest in exploring quality of life as a primary end point for cancer therapy has established a need for prospective, controlled studies to assess baseline and serial quality-of-life parameters in brain tumor patients in order to plan and evaluate appropriate and timely interventions for their symptoms.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Health-related quality of life has become an important end point in modern day clinical practice in patients with primary or secondary brain tumors. Patients have unique symptoms and problems from diagnosis till death, which require interventions that are multidisciplinary in nature. Here, we review and summarize the various key issues in palliative care, quality of life and end of life in patients with brain tumors, with the focus on primary gliomas.
    08/2014; 6:71. DOI:10.12703/P6-71
  • Source
    Ana Sanz Cortés, Maria Eugenia Olivares Crespo
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical symptoms of anxiety and depression as well as cognitive impairment determine the quality of life of patients with brain tumors (Liu, Page, Solheim, Fox, & Chang, 2009). The aim of this paper is to analyze the quality of life and its relationship to psychological variables in individuals diagnosed with glioma six months earlier. The sample consisted of 28 patients (58.6% male) with a mean age of 54.38 and 89.2% of them receiving adjuvant therapy (chemotherapy). All subjects were administered a neuropsychological battery assessing quaility of life, anxiety and depression, attention, memory, language, visuoconstructive skills, visual organization, language, and executive functions. These patients have a worse quality of life in certain dimensions (physical, functional, family) and overall perception of well-being. All areas of quality of life are associated with mood and the presence of clinical manifestations of depression accounts for a lower quality of life. On the other hand, improved cognitive performance in object recognition processes, memory, and planning indicates a higher overall quality of life of these patients.
    Clínica y Salud 03/2015; 1. DOI:10.1016/j.clysa.2014.07.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Low-grade glioma (LGG) comprise nearly 20% of all central nervous system (CNS) glial tumors with approximately 2000-3000 patients diagnosed annually in the United States. Due to their infiltrative ability and aggressive nature, the average 10-year survival is 30% when <90% of the tumor is resected. Since the 1970s, prognosis for LGGs has significantly improved. This improvement is primarily due to earlier diagnosis by the MRI scan, increased awareness of the more favorable oligo component, technical advances in intraoperative neurosurgery, and stratification for young age. Utilizing a number of prognostic factors, LGG have been classified into low-risk and high-risk subgroups. Optimal therapy for patients with low-risk, supratentorial grade II glioma remains a highly controversial issue in the neuro-oncology community. The concerns regarding the toxicity of therapy often outweigh the benefits of delaying tumor progression. The recommendation for observation is made without full prospective understanding of the impact of radiological tumor progression on the quality of life (QOL), neurocognitive function (NCF), seizure control, and functional status of these patients. We present a review of the current knowledge of the management of LGG with emphasis upon patient reported outcomes (PROs) of QOL, NCF, and seizure control. We also discuss current clinical trials with proposals to evaluate QOL, NCF, and seizure control in patients undergoing observation alone after newly diagnosed low-risk LGG or treatment options for those patients in the high-risk group.
    World Neurosurgery 07/2014; 82(1-2). DOI:10.1016/j.wneu.2014.02.033 · 2.42 Impact Factor

Full-text (2 Sources)

Available from
May 31, 2014